AJJ Medtech FY2025 Annual Report: The Fundamentals Are Improving
$AJJ Medtech(584.SG)
AJJ Medtech (SGX: 584) is not only showing higher revenue and narrower losses in FY2025.
Two points may matter more than they first appear:
• continued support from major shareholders and management during the current scaling phase
• growing certification and regulatory capabilities, which may become a real moat in healthcare
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
